What “Negotiating” With Medicare Means For Drug Makers: A Mixture Of Price Controls And Actual Negotiations

What “Negotiating” With Medicare Means For Drug Makers: A Mixture Of Price Controls And Actual Negotiations

Source: 
Forbes
snippet: 

In the debate on the drug pricing provisions contained in the Inflation Reduction Act, critics call the government-mandated process “price controls.” Specifically, they’re referring to the relatively small number of drugs that will be selected for price negotiation with the Centers for Medicare and Medicaid Services (CMS).